Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India Extends Grants To Drug Makers For Neglected Diseases

This article was originally published in PharmAsia News

Executive Summary

A Cabinet committee of the Indian government approved a provision to extend grants to drug makers to encourage development of drugs for neglected diseases. The grants would include research for treatments for malaria, tuberculosis, kala-azar, filariasis and other diseases pharma companies are generally not developing, but which are considered a threat in tropical India. Under the current plan that would be extended by the Cabinet Committee on Economic Affairs, drug makers would be eligible for soft loans for up to 70 percent of the total project cost at 3 percent interest for 10 years. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts